
A study assessed the interchangeability of adalimumab biosimilar PF-06410293 (adalimumab-afzb) and reference adalimumab, aiming to increase access to effective treatment. The study involved 445 patients across ten countries and found no significant differences in pharmacokinetics, safety, or efficacy between the biosimilar and reference adalimumab. This suggests that multiple switches between the two are as safe and effective as using reference adalimumab alone, potentially expanding treatment options for rheumatoid arthritis patients.
Like
Save
Share